Clinical Efficacy of Modified Shenling Baizhu San in Treatment of Hashimoto's Thyroiditis
10.13422/j.cnki.syfjx.20190925
- VernacularTitle: 加味参苓白术散治疗桥本氏甲状腺炎的临床观察
- Author:
Xiao-ming CHEN
1
;
Mei-xiang CAI
2
;
Li-ming ZHUANG
1
;
Liang-qin LUO
1
;
Xiang-yang CAI
1
Author Information
1. The Second Affiliated Hospital of Fujian Medical University, Quanzhou 362000, China
2. Quanzhou Third Hospital, Quanzhou 362000, China
- Publication Type:Research Article
- Keywords:
Shenling Baizhu San;
Hashimoto's thyroiditis (HT);
integrated traditional Chinese and western medicine;
clinical observation;
adverse reactions
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2019;25(10):15-19
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To observe the clinical efficacy of modified Shenling Baizhu San combined with thyroxine tablets in the treatment of Hashimoto's thyroiditis (HT). Method:The 68 patients with HT were randomly divided into treatment group and control group, with 34 patients in each group. Control group was treated with thyroxine tablets alone, while treatment group was treated with modified Shenling Baizhu San in addition to the therapy of control group. Free triiodothyronine (FT3), free Thyroxine (FT4), thyroid stimulating hormone (TSH), serum thyroid peroxidase antibody (TPOAb) and thyroglobulin were observed before and after treatment in the two groups of HT patients. The changes of thyroglobulin antibody (TgAb) and traditional Chinese medicine (TCM) syndrome score, and the safety of TCM prescription were observed. Result:After 3 months of treatment, the effective rate of treatment group was 91.2%, which was significantly higher than 70.6% of control group, with statistically significant difference (P<0.05); after 3 months of treatment, the scores of TCM syndromes in two groups were significantly lower than those before treatment (P<0.05), and the scores of TCM syndromes in treatment group were significantly lower than those in control group (P<0.05). FT3 and FT4 in treatment group and control group increased significantly after 3 months of treatment (P<0.01), but treatment group increased more significantly than control group (P<0.01); TSH, TgAb and TPOAb in treatment group and control group decreased significantly after 3 months of treatment (P<0.05), and treatment group decreased more significantly than before treatment (P<0.05), with no adverse reaction during the treatment. Conclusion:Modified Shenling Baizhu San combined with thyroxine tablets in the treatment of HT is more effective than simple thyroxine tablets, which is worthy of further clinical and experimental study.
